Use of BTK inhibitors with focus on ibrutinib in mantle cell lymphoma: an expert panel opinion statement.
Sign Up to like & getrecommendations! Published in 2022 at "Hematological oncology"
DOI: 10.1002/hon.2983
Abstract: The introduction of BTK inhibitors transformed the management of patients with mantle cell lymphoma (MCL). Ibrutinib, the first-in-class BTK inhibitor is now approved in more than 80 countries and there are over 20 new BTK… read more here.
Keywords: opinion statement; mantle cell; cell lymphoma; btk inhibitors ... See more keywords